CHDI
Autophagy in Neurodegeneration and Neuroprotection: A Therapeutic Perspective
CHDI and Icahn School of Medicine at Mount Sinai are co-sponsoring a one day symp ...Read More
PLoS Currents: Huntington Disease
Immediately sharing research results and ideas while ensuring that they will be permanently archived and citable. ...Read More
Alnylam, Medtronic, and CHDI Foundation Form Collaboration to Advance RNAi Therapeutics for the Treatment of Huntington’s Disease
Cambridge, Mass., Minneapolis, and New York City – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), Medtronic Inc. (NYSE:MDT), and CHDI Foundation, Inc., announced today that they have formed a collaboration to advance ALN-HTT, a novel drug-device ...Read More